Literature DB >> 12237156

Mammalian peptide transporters as targets for drug delivery.

Isabel Rubio-Aliaga1, Hannelore Daniel.   

Abstract

Peptide transporters are integral plasma membrane proteins that mediate the cellular uptake of dipeptides and tripeptides in addition to a variety of peptidomimetics. The carriers, which occur predominantly in the brush-border membranes of epithelial cells of the small intestine, lung, choroid plexus and kidney, contribute to absorption, distribution and elimination of their substrates. The cellular uptake of peptides and peptidomimetics involves the cotransport of protons down an inwardly directed, electrochemical proton gradient that provides the driving force and causes the electrogenicity of the translocation step. Peptide transporters represent excellent targets for the delivery of pharmacologically active compounds because their substrate-binding site can accommodate a wide range of molecules of differing size, hydrophobicity and charge.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237156     DOI: 10.1016/s0165-6147(02)02072-2

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  62 in total

1.  ABC and SLC transporter expression and proton oligopeptide transporter (POT) mediated permeation across the human blood--brain barrier cell line, hCMEC/D3 [corrected].

Authors:  Stephen M Carl; David J Lindley; Debanjan Das; Pierre O Couraud; Babette B Weksler; Ignacio Romero; Stephanie A Mowery; Gregory T Knipp
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

2.  Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.

Authors:  Apeng Wang; Shuo Wu; Zeyu Tao; Xiaoning Li; Kai Lv; Chao Ma; Yuhuan Li; Linhu Li; Mingliang Liu
Journal:  ACS Med Chem Lett       Date:  2019-05-16       Impact factor: 4.345

3.  Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPT1.

Authors:  Monica Sala-Rabanal; Donald D F Loo; Bruce A Hirayama; Eric Turk; Ernest M Wright
Journal:  J Physiol       Date:  2006-04-20       Impact factor: 5.182

4.  In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and PepT1 knockout mice.

Authors:  Maria M Posada; David E Smith
Journal:  Pharm Res       Date:  2013-11       Impact factor: 4.200

5.  Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study.

Authors:  Xiaomei Chen; Richard F Keep; Yan Liang; Hao-Jie Zhu; Margareta Hammarlund-Udenaes; Yongjun Hu; David E Smith
Journal:  Biochem Pharmacol       Date:  2017-02-10       Impact factor: 5.858

6.  Comparative analysis of vertebrate PEPT1 and PEPT2 genes.

Authors:  Minghui Wang; Xiangzhe Zhang; Hongbo Zhao; Qishan Wang; Yuchun Pan
Journal:  Genetica       Date:  2009-12-20       Impact factor: 1.082

7.  Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers.

Authors:  Deepak Gupta; Sheeba Varghese Gupta; Kyung-Dall Lee; Gordon L Amidon
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

8.  Phenotype analysis of mice deficient in the peptide transporter PEPT2 in response to alterations in dietary protein intake.

Authors:  Isabelle M Frey; Isabel Rubio-Aliaga; Martina Klempt; Eckhard Wolf; Hannelore Daniel
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

9.  Glycyl-L-glutamine disposition in rat choroid plexus epithelial cells in primary culture: role of PEPT2.

Authors:  Yongjun Hu; Scott M Ocheltree; Jianming Xiang; Richard F Keep; David E Smith
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

10.  Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin.

Authors:  Hugues Chanteux; Isabelle Paternotte; Marie-Paule Mingeot-Leclercq; Robert Brasseur; E Sonveaux; Paul M Tulkens
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.